NO20085050L - Metoder for legemiddeladministrering - Google Patents

Metoder for legemiddeladministrering

Info

Publication number
NO20085050L
NO20085050L NO20085050A NO20085050A NO20085050L NO 20085050 L NO20085050 L NO 20085050L NO 20085050 A NO20085050 A NO 20085050A NO 20085050 A NO20085050 A NO 20085050A NO 20085050 L NO20085050 L NO 20085050L
Authority
NO
Norway
Prior art keywords
methods
drug administration
formula
adverse effect
potentially adverse
Prior art date
Application number
NO20085050A
Other languages
English (en)
Norwegian (no)
Inventor
Jeffrey P Whitten
John Lim
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of NO20085050L publication Critical patent/NO20085050L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20085050A 2006-06-03 2008-12-04 Metoder for legemiddeladministrering NO20085050L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80386406P 2006-06-03 2006-06-03
US80597506P 2006-06-27 2006-06-27
US82111506P 2006-08-01 2006-08-01
US85798806P 2006-11-08 2006-11-08
US93932607P 2007-05-21 2007-05-21
PCT/US2007/070272 WO2007143587A1 (en) 2006-06-03 2007-06-01 Drug administration methods

Publications (1)

Publication Number Publication Date
NO20085050L true NO20085050L (no) 2008-12-17

Family

ID=38801825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085050A NO20085050L (no) 2006-06-03 2008-12-04 Metoder for legemiddeladministrering

Country Status (11)

Country Link
US (1) US20070293485A1 (de)
EP (1) EP2023935A4 (de)
JP (1) JP2009539774A (de)
KR (1) KR20090021211A (de)
AU (1) AU2007256698A1 (de)
BR (1) BRPI0713094A2 (de)
CA (1) CA2654151A1 (de)
IL (1) IL195618A0 (de)
MX (1) MX2008015399A (de)
NO (1) NO20085050L (de)
WO (1) WO2007143587A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002870A1 (en) * 2007-06-22 2008-12-31 Cylene Pharmaceuticals, Inc. Methods for treating aberrant cell proliferation disorders
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US6528517B1 (en) * 1998-02-04 2003-03-04 Board Of Regents, The University Of Texas System Synthesis of quinobenzoxazine analogues with topoisomerase II and quadruplex interactions for use as antineoplastic agents
NZ543006A (en) * 2003-04-07 2009-03-31 Cylene Pharmaceuticals Inc Substituted quinobenzoxazine analogs
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
BRPI0514857A (pt) * 2004-09-03 2008-05-06 Celgene Corp composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central

Also Published As

Publication number Publication date
EP2023935A4 (de) 2010-12-22
IL195618A0 (en) 2009-09-01
AU2007256698A1 (en) 2007-12-13
MX2008015399A (es) 2009-02-06
BRPI0713094A2 (pt) 2012-10-16
US20070293485A1 (en) 2007-12-20
WO2007143587A8 (en) 2008-04-03
KR20090021211A (ko) 2009-02-27
EP2023935A1 (de) 2009-02-18
CA2654151A1 (en) 2007-12-13
JP2009539774A (ja) 2009-11-19
WO2007143587A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
PE20080140A1 (es) DERIVADOS DE CINAMIDA MULTICICLICOS COMO INHIBIDORES DE ß AMILOIDE
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
MY149622A (en) Pyrazoles as 11-beta-hsd-1
HK1203497A1 (en) Non-systemic tgr5 agonists
WO2014002051A3 (en) Complement pathway modulators and uses thereof
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
WO2014002058A3 (en) Complement pathway modulators and uses thereof
HK1206017A1 (en) Complement pathway modulators and uses thereof
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
CY1111793T1 (el) Μυκητοκτονες συνθεσεις
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2007135527A3 (en) Benzimidazolyl compounds
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
WO2007084728A3 (en) 2-imino-benzimidazoles
CY1117860T1 (el) Διαβλεννογονια χορηγηση 2-(10-υδροξυδεκυλ)-5,6-διμεθοξυ-3-μεθυλ-2,5-κυκλοεξαδιενο-1,4-διονης (ιδεβενονη)
TW200637810A (en) Substituted N-aminomethylenesulfonamides, their preparation and use as medicaments
WO2010130773A3 (en) Benzoxazolone derivatives as aldosterone symthase inhibitors
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
WO2012140596A8 (en) Glycoside derivatives and uses thereof
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
NO20084543L (no) Benzimidazolderivater
WO2009051223A1 (ja) 白内障処置のための医薬組成物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application